Compass Therapeutics, Inc.

CMPXNASDAQHealthcare● Active

$2.02

$-0.02(-0.98%)

Market Cap$279338328

P/E Ratio—

52W High$6.88

52W Low$1.61

Avg Volume7.5M

Open$2.04

Beta0.74

Insider Trades Ownership Employees

Compass Therapeutics, Inc. (CMPX) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · CMPX · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

2.50

Buy/Sell (by trades)

Overall sentiment

BULLISH

↑ Buy 71%Active transactions only · RSU vesting excluded29% Sell ↓

Compass Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

CMPX insider buying and selling by quarter

CMPX insider selling · CMPX insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

7.1M3.6M0

2024 Q1

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · CMPX ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

CMPX executive sell shares · CMPX board member insider trading · CMPX insider trading SEC filing

Showing 37 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Apr 29, 2026	Anderman Jonathan General Counsel	Award	25,000	$1.89	$47K	196,000	Form 4
Apr 29, 2026	Lerner Neil CAO	Award	15,000	$1.89	$28K	397,500	Form 4
Feb 8, 2026	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Other	36,687	$6.52	$239K	6,603,336	Form 4
Jan 9, 2026	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Other	46,777	$5.35	$250K	6,640,023	Form 4
Jan 2, 2026	Shin Barry CFO	Award	125,000	$5.17	$646K	525,000	Form 4
Jan 2, 2026	Schuetz Thomas J. CEO · Director	Award	250,000	$5.17	$1.29M⚡	6,686,800	Form 4
Jan 2, 2026	Lerner Neil CAO	Award	62,500	$5.17	$323K	382,500	Form 4
Jan 2, 2026	Anderman Jonathan General Counsel	Award	150,000	$5.17	$776K	171,000	Form 4
Nov 16, 2025	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Other	44,025	$4.83	$213K	6,436,800	Form 4
May 27, 2025	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Purchase	10,000	$2.11	$21K	6,480,825	Form 4
Apr 9, 2025	GORDON CARL L Director	Sale	3,571,428	$1.59	$5.68M⚡	0	Form 4
Apr 9, 2025	ORBIMED ADVISORS LLC Director	Sale	3,571,428	$1.59	$5.68M⚡	0	Form 4
Apr 7, 2025	Anderman Jonathan Gen Counsel & Corporate Sec	Purchase	20,000	$1.54	$31K	21,000	Form 4
Apr 7, 2025	Lerner Neil CHIEF ACCOUNTING OFFICER	Purchase	20,000	$1.42	$28K	320,000	Form 4
Feb 8, 2025	Schuetz Thomas J. CEO · Director	Other	41,687	$3.50	$146K	6,470,825	Form 4
Jan 9, 2025	Schuetz Thomas J. CEO · Director	Other	58,054	$1.86	$108K	6,512,512	Form 4
Dec 9, 2024	Shin Barry CFO	Award	400,000	$1.65	$660K	400,000	Form 4
Feb 8, 2024	Bisker-Leib Vered CHIEF EXECUTIVE OFFICER · Director	Other	49,198	$1.45	$71K	3,124,426	Form 4
Feb 8, 2024	Schuetz Thomas J. PRESIDENT · Director	Other	44,782	$1.45	$65K	6,570,566	Form 4
Jan 9, 2024	Bisker-Leib Vered CEO · Director	Award	1,753,125	$1.93	$3.38M⚡	3,173,624	Form 4
Jan 9, 2024	Schuetz Thomas J. President of R&D · Director	Award	637,500	$1.93	$1.23M⚡	6,615,348	Form 4
Nov 17, 2023	Bisker-Leib Vered COO	Other	64,415	$1.50	$97K	1,420,499	Form 4
Nov 17, 2023	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Other	44,025	$1.50	$66K	5,977,848	Form 4
Mar 10, 2023	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Purchase	10,000	$3.37	$34K	6,021,873	Form 4
Feb 27, 2023	Schuetz Thomas J. CHIEF EXECUTIVE OFFICER · Director	Purchase	20,000	$3.98	$80K	6,011,873	Form 4

Anderman Jonathan

General Counsel

Award

Date

Apr 29

25,000

Price

$1.89

Value

$47K

View Form 4 on SEC.gov

Lerner Neil

CAO

Award

Date

Apr 29

15,000

Price

$1.89

Value

$28K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Other

Date

Feb 8

36,687

Price

$6.52

Value

$239K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Other

Date

Jan 9

46,777

Price

$5.35

Value

$250K

View Form 4 on SEC.gov

Shin Barry

CFO

Award

Date

Jan 2

125,000

Price

$5.17

Value

$646K

View Form 4 on SEC.gov

Schuetz Thomas J.

CEO · Director

Award

Date

Jan 2

250,000

Price

$5.17

Value

$1.29M ⚡

View Form 4 on SEC.gov

Lerner Neil

CAO

Award

Date

Jan 2

62,500

Price

$5.17

Value

$323K

View Form 4 on SEC.gov

Anderman Jonathan

General Counsel

Award

Date

Jan 2

150,000

Price

$5.17

Value

$776K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Other

Date

Nov 16

44,025

Price

$4.83

Value

$213K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Purchase

Date

May 27

10,000

Price

$2.11

Value

$21K

View Form 4 on SEC.gov

GORDON CARL L

Director

Sale

Date

Apr 9

3,571,428

Price

$1.59

Value

$5.68M ⚡

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

Director

Sale

Date

Apr 9

3,571,428

Price

$1.59

Value

$5.68M ⚡

View Form 4 on SEC.gov

Anderman Jonathan

Gen Counsel & Corporate Sec

Purchase

Date

Apr 7

20,000

Price

$1.54

Value

$31K

View Form 4 on SEC.gov

Lerner Neil

CHIEF ACCOUNTING OFFICER

Purchase

Date

Apr 7

20,000

Price

$1.42

Value

$28K

View Form 4 on SEC.gov

Schuetz Thomas J.

CEO · Director

Other

Date

Feb 8

41,687

Price

$3.50

Value

$146K

View Form 4 on SEC.gov

Schuetz Thomas J.

CEO · Director

Other

Date

Jan 9

58,054

Price

$1.86

Value

$108K

View Form 4 on SEC.gov

Shin Barry

CFO

Award

Date

Dec 9

400,000

Price

$1.65

Value

$660K

View Form 4 on SEC.gov

Bisker-Leib Vered

CHIEF EXECUTIVE OFFICER · Director

Other

Date

Feb 8

49,198

Price

$1.45

Value

$71K

View Form 4 on SEC.gov

Schuetz Thomas J.

PRESIDENT · Director

Other

Date

Feb 8

44,782

Price

$1.45

Value

$65K

View Form 4 on SEC.gov

Bisker-Leib Vered

CEO · Director

Award

Date

Jan 9

1,753,125

Price

$1.93

Value

$3.38M ⚡

View Form 4 on SEC.gov

Schuetz Thomas J.

President of R&D · Director

Award

Date

Jan 9

637,500

Price

$1.93

Value

$1.23M ⚡

View Form 4 on SEC.gov

Bisker-Leib Vered

COO

Other

Date

Nov 17

64,415

Price

$1.50

Value

$97K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Other

Date

Nov 17

44,025

Price

$1.50

Value

$66K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Purchase

Date

Mar 10

10,000

Price

$3.37

Value

$34K

View Form 4 on SEC.gov

Schuetz Thomas J.

CHIEF EXECUTIVE OFFICER · Director

Purchase

Date

Feb 27

20,000

Price

$3.98

Value

$80K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About CMPX insider trading

CMPX insider trades

Compass Therapeutics, Inc. (CMPX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER · Director), Anderman Jonathan (General Counsel), Lerner Neil (CAO). Over the past 12 months, 4 insiders have filed transactions with the SEC. CMPX insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Compass Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

CMPX insider trading · 5 questions

The insiders of Compass Therapeutics, Inc. (CMPX) include executives and directors such as Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER · Director), Anderman Jonathan (General Counsel), Lerner Neil (CAO), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

CMPX board member insider tradingwho are CMPX insidersCMPX insider rosterCompass Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026